Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Joel Shertok, PhD, Member of The Board, Business Development and Process Designer of a Global AI-based External Relations Prospecting System for LPBI Group

Effective June 23, 2020 –  Nominated as Member of the Board

Affiliation with LPBI Group:

12/22/2019 – 5/4/2021

Roles at LPBI Group: Updated on 8/15/2020

Verticals:

(1) Chemical Industry

(2) Financials & Insurance: Health Care

(3) Biotech

(4) Private Equity

Business Development responsibilities @LPBI:

(1) All Documentation Artifacts expected by External Relation

(2) Client facing engagement with External relations: Information Syndication

(3) Development of a Bot-based Global Prospecting System for LPBI

3.1 applications on ALA’s 7,300

3.2 applications on JTS’s 1st degree connections on LinkedIn

(4) LPBI’s LEAD all efforts with IB

(5) LPBI’s LEAD for all Partnerships:

5.1 LPBI J-V (30%) with ABI-Lab (70%)

5.2 BurstIQ

5.3 Agreements with Wolfram Machine Learning Approach https://www.wolfram.com/featureset/machine-learning/ 

Plan for Business Development Activity at 1.0 LPBI 4Q 2020

• 1,4,5, ABOVE

Roles on 2.0 LPBI Group’s TNS #1,2,3,4,5,6 https://pharmaceuticalintelligence.com/vision/

• 2,3,5, ABOVE

TNS #1: See 5.3, above – TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market

TNS #2: See 5.2, above, Blockchain Transactions and broadcasting to communities in the Health Care Sector – THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: BustIQ – lined them up and are willing to build the Front End

TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA

TNS #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio  [SEE New Yorker] – HAS POTENTIAL

TNS #5: See 5.1, above Joint venture with Dr. Nir for Drug Discovery: 

TNS #6:  e-Books Translations into Japanese, Spanish, Russian 

Plan for Business Development Activity at 2.0 LPBI 1Q 2021

• See 5.1, 5.2, 5.3, above

In addition to aforementioned points, Joel will continue his engagement with the following activities:

• Consult to Founder on all business development issues, own opinion sought of
• Designer of Procedures for LPBI Group’s Business Development Practice
• Designer of a Global AI-based External Relations Prospecting System for LPBI Group’s Exit Efforts, including BOT-based technology
• Developer of modules for 12 economic segments to implement BOT-based technology for dynamic prospecting of M&A strategic acquirer and private equity funds investors
• Business Plan development and document creations based on output of BOT-based technology, VISTA 2019/2020 repository and other sources

Expertise declared in the following Research Categories on our Journal Ontology:

1. BioTech – Venture Formation
2. Commercialization
3. Conference with Social Media
4. Global Partnering and BioTech Invention
5. Healthcare Reform
6. Innovation
7. Investment in Technological Breakthrough
8. Material Science and Engineering
9. Pharma Industry Competitive Intelligence
10. Pharmaceutical R&D and Investment
11. Technology Transfer – Biotech and Pharma
12. Venture Capital

BIO

Dr. Joel Shertok

jshertok@processindconsultants.com  

302-562-9759

Executive Biography

Summary: Dr. Joel Shertok is a senior level executive who has over 40 years’ experience in the chemical process industries. His track record is characterized by: merger and acquisition experience, development of new product lines for his companies, creation of new business ventures, creation/motivation of new business teams, and international investigations of novel technologies.

Senior Product Manager for Amoco Performance Products’ Carbon Fiber Pre-preg Business Segment, Dr. Shertok championed the formation and subsequent creation of a new multifunction Business Team to manage all aspects of this new business venture. Revenues went from $0 to $20MM in three years at gross margins of 30%.

Manufacturing Manager for Amoco BioProducts Corporation, Dr. Shertok set up a network of toll manufacturers to allow the manufacture of 25-hydroxyvitamin D3 for the poultry market, sparing Amoco the need to make capital investments in a new business. This small business generated revenues of $1MM in its second year.

Dr. Shertok is currently on the Board of a Solar Cell start-up: T3DP, which has novel technology for the manufacture of 3 – Dimensional solar cells via 3D printing. This technology promises to greatly increase solar cell efficiency. Dr. Shertok has provided close guidance to the company founders in obtaining funding for commercialization.

Dr. Shertok is working closely with, and supporting customer/technology development, for a second start-up, Crystal Clear Technologies, which has developed a novel media, based on chitosan, for the removal of ppb levels of selenium from scrub wathter of coal-fired power plants.

As an Entrepreneur in Residence (EIR) for New York State’s R/D Authority, NYSERDA, Dr. Shertok is working with several start-ups in developing business plans, funding, and technology development.

Dr. Shertok is working with start-up AvantFluor to develop a business/commercialization plan for a novel technology to manufacture SF4 materials.

Dr. Shertok is on the Board of a Consultant Group, The Right Process, (www.therightprocess.com) advising companies on improving their business processes.

As a senior executive at Gelman Sciences (later acquired by Pall Corporation), Dr. Shertok took a small 9-person R/D group, and expanded/reorganized it into a 29-person, high productivity organization which developed new membranes lines for diagnostic testing and protein differentiation.

M&A Transactions: As an executive with Graver Technologies, Dr. Shertok spearheaded the acquisition of three companies: a small industrial filter group ($300K incremental revenues), the water filtration business Whatman Corporation ($3MM incremental revenues), and a start-up business developing a new media for arsenic removal from water (potentially $1MM in incremental revenue). Dr. Shertok is also working with Private Equity organizations (Blackmore Partners –Chicago) to develop new business strategies to implement.

Professional Experience: In 2014, Dr. Shertok formed Process Industries Consultants, Inc., an “S” Corporation providing expertise in the chemical process and materials industries. Dr. Shertok has been retained by clients to provide input for filtration issues, activated carbon technology, carbon block costing, reaction engineering, formulated products, and separations/purification. He has also developed successful foundation grant requests for Delaware non-profits.

Dr. Shertok also provides technical expertise to Advanced Plasma Solutions, a start-up located in Malvern, PA. Previously, Dr. Shertok has been a Research Fellow at Rochester Institute of Technology. He has held senior technical and managerial positions at Rochester Midland Corporation (formulated products and sanitizers, Graver Technologies (filtration and purification), Pall-Gelman Corporation (membrane filtration and water purification), Amoco Corporation (Carbon fiber composites and BioTechnology), and Union Carbide (specialty chemicals).